134 related articles for article (PubMed ID: 17431114)
1. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.
Liu TJ; LaFortune T; Honda T; Ohmori O; Hatakeyama S; Meyer T; Jackson D; de Groot J; Yung WK
Mol Cancer Ther; 2007 Apr; 6(4):1357-67. PubMed ID: 17431114
[TBL] [Abstract][Full Text] [Related]
2. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
Flanigan SA; Pitts TM; Eckhardt SG; Tentler JJ; Tan AC; Thorburn A; Leong S
Clin Cancer Res; 2010 Nov; 16(22):5436-46. PubMed ID: 20943761
[TBL] [Abstract][Full Text] [Related]
3. Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.
Golubovskaya VM; Ho B; Zheng M; Magis A; Ostrov D; Morrison C; Cance WG
BMC Cancer; 2013 Jul; 13():342. PubMed ID: 23841915
[TBL] [Abstract][Full Text] [Related]
4. Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival.
Gillory LA; Stewart JE; Megison ML; Waters AM; Beierle EA
J Surg Res; 2015 Jun; 196(2):339-49. PubMed ID: 25862488
[TBL] [Abstract][Full Text] [Related]
5. LAIR1 drives glioma progression by nuclear focal adhesion kinase dependent expressions of cyclin D1 and immunosuppressive chemokines/cytokines.
Wei X; Pan S; Wang Z; Chen J; Lu L; Cao Q; Song S; Zhang H; Liu X; Qu X; Lin X; Xu H
Cell Death Dis; 2023 Oct; 14(10):684. PubMed ID: 37845206
[TBL] [Abstract][Full Text] [Related]
6. The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor.
Aye JM; Stafman LL; Williams AP; Garner EF; Stewart JE; Anderson JC; Mruthyunjayappa S; Waldrop MG; Goolsby CD; Markert HR; Quinn C; Marayati R; Mroczek-Musulman E; Willey CD; Yoon KJ; Whelan KF; Beierle EA
Oncotarget; 2019 Sep; 10(53):5534-5548. PubMed ID: 31565187
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors.
Li R; Gong L; Sun J; Liang Z; He J; Huang J; Ning X; Song H; Li R; Zhang Q; Lin Z; Yin Y
Bioorg Chem; 2024 Mar; 144():107134. PubMed ID: 38237389
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
[TBL] [Abstract][Full Text] [Related]
9. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
Zhang J; He DH; Zajac-Kaye M; Hochwald SN
Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
Halder J; Lin YG; Merritt WM; Spannuth WA; Nick AM; Honda T; Kamat AA; Han LY; Kim TJ; Lu C; Tari AM; Bornmann W; Fernandez A; Lopez-Berestein G; Sood AK
Cancer Res; 2007 Nov; 67(22):10976-83. PubMed ID: 18006843
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.
Fukami S; Tomioka D; Murakami Y; Honda T; Hatakeyama S
BMC Res Notes; 2019 Jun; 12(1):347. PubMed ID: 31215459
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
Stokes JB; Adair SJ; Slack-Davis JK; Walters DM; Tilghman RW; Hershey ED; Lowrey B; Thomas KS; Bouton AH; Hwang RF; Stelow EB; Parsons JT; Bauer TW
Mol Cancer Ther; 2011 Nov; 10(11):2135-45. PubMed ID: 21903606
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
15. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis.
Zhao X; Guan JL
Adv Drug Deliv Rev; 2011 Jul; 63(8):610-5. PubMed ID: 21118706
[TBL] [Abstract][Full Text] [Related]
16. TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis.
Schultze A; Decker S; Otten J; Horst AK; Vohwinkel G; Schuch G; Bokemeyer C; Loges S; Fiedler W
Invest New Drugs; 2010 Dec; 28(6):825-33. PubMed ID: 19784551
[TBL] [Abstract][Full Text] [Related]
17. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
Watanabe N; Takaoka M; Sakurama K; Tomono Y; Hatakeyama S; Ohmori O; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Beer DG; Nagatsuka H; Tanaka N; Naomoto Y
Clin Cancer Res; 2008 Jul; 14(14):4631-9. PubMed ID: 18628478
[TBL] [Abstract][Full Text] [Related]
18. TAE226 inhibits human neuroblastoma cell survival.
Beierle EA; Trujillo A; Nagaram A; Golubovskaya VM; Cance WG; Kurenova EV
Cancer Invest; 2008 Mar; 26(2):145-51. PubMed ID: 18259944
[TBL] [Abstract][Full Text] [Related]
19. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.
Golubovskaya VM; Virnig C; Cance WG
Mol Carcinog; 2008 Mar; 47(3):222-34. PubMed ID: 17849451
[TBL] [Abstract][Full Text] [Related]
20. Focal adhesion kinase: from biological functions to therapeutic strategies.
Tan X; Yan Y; Song B; Zhu S; Mei Q; Wu K
Exp Hematol Oncol; 2023 Sep; 12(1):83. PubMed ID: 37749625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]